Castle Biosciences (CSTL) Operating Income (2018 - 2026)
Castle Biosciences' Operating Income history spans 8 years, with the latest figure at -$3.8 million for Q4 2025.
- On a quarterly basis, Operating Income fell 194.49% to -$3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$42.8 million, a 593.77% decrease, with the full-year FY2025 number at -$42.8 million, down 593.77% from a year prior.
- Operating Income hit -$3.8 million in Q4 2025 for Castle Biosciences, up from -$6.8 million in the prior quarter.
- Over the last five years, Operating Income for CSTL hit a ceiling of $5.1 million in Q3 2024 and a floor of -$31.5 million in Q1 2023.
- Historically, Operating Income has averaged -$10.8 million across 5 years, with a median of -$7.8 million in 2021.
- Biggest five-year swings in Operating Income: plummeted 1265.89% in 2021 and later surged 171.58% in 2024.
- Tracing CSTL's Operating Income over 5 years: stood at -$15.2 million in 2021, then plummeted by 50.5% to -$22.8 million in 2022, then soared by 75.22% to -$5.7 million in 2023, then soared by 171.58% to $4.0 million in 2024, then crashed by 194.49% to -$3.8 million in 2025.
- Business Quant data shows Operating Income for CSTL at -$3.8 million in Q4 2025, -$6.8 million in Q3 2025, and -$4.3 million in Q2 2025.